GCC Vaccine Market Size Worth US$ 503 Million during 2023-2028, With a CAGR of 6.4% | IMARC Group

According to IMARC Group's latest research report, titled "GCC Vaccine Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028," offers a comprehensive analysis of the industry, which comprises insights on the GCC vaccine market. The report also includes competitor and regional analysis, and contemporary advancements in the market. The GCC vaccine market size reached US$ 343 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 503 Million by 2028, exhibiting a growth rate (CAGR) of 6.4% during 2023-2028.

GCC Vaccine Market Overview:

The vaccine is an essential medical tool designed to stimulate the body's immune system to develop resistance to specific diseases. It has played a pivotal role in preventing and controlling infectious diseases for decades. It has been instrumental in eradicating or significantly reducing the prevalence of deadly diseases such as polio, smallpox, and measles. It has saved countless lives and improved public health on a global scale.

Additionally, it can prevent the spread of contagious diseases, creating collective immunity within communities and protecting vulnerable individuals who cannot be vaccinated themselves. It also contributes to increased productivity by reducing illness-related absenteeism from work and school. Furthermore, it is safe and rigorously tested before approval, with ongoing monitoring to ensure their safety and efficacy.

Get Sample Copy of Report at - https://www.imarcgroup.com/gcc-vaccine-market/requestsample

GCC Vaccine Market Trends:

The growing and aging population is driving the market in GCC. Additionally, the GCC governments have invested significantly in their healthcare infrastructure, including the expansion of vaccination programs. Public and private healthcare providers have played a crucial role in making vaccines accessible to a broader segment of the population.

Moreover, collaborations and partnerships between GCC countries and global pharmaceutical companies have facilitated the availability of a wide range of vaccines. These collaborations have not only ensured a steady supply of vaccines but have also supported research and development efforts for new vaccines. The GCC region's commitment to maintaining high healthcare standards and its efforts to diversify the healthcare sector have contributed to the growth of the vaccine market. With a focus on research and innovation, the region is becoming a hub for vaccine development and production.

Explore the Full Report with Charts, Table of Contents, and List of Figures: https://www.imarcgroup.com/gcc-vaccine-market

Key Market Segmentation:

Breakup by Technology:

• Conjugate Vaccines
• Inactivated and Subunit Vaccines
• Live Attenuated Vaccines
• Recombinant Vaccines
• Toxoid Vaccines
• Others

Breakup by Patient Type:

• Paediatric
• Adult

Breakup by Indication:

• Bacterial Diseases
o Meningococcal Disease
o Pneumococcal Disease
o Diphtheria/Tetanus/Pertussis (DPT)
o Tuberculosis
o Haemophilus Influenzae (Hib)
o Typhoid
o Others
• Viral Diseases
o Hepatitis
o Influenza
o Human Papillomavirus (HPV)
o Measles/Mumps/Rubella (MMR)
o Rotavirus
o Herpes Zoster
o Varicella
o Japanese Encephalitis
o Rubella
o Polio
o Rabies
o Dengue
o Others

Breakup by Route of Administration:

• Intramuscular and Subcutaneous Administration
• Oral Administration
• Others

Breakup by Product Type:

• Multivalent Vaccine
• Monovalent Vaccine

Breakup by Treatment Type:

• Preventive Vaccine
• Therapeutic Vaccine

Breakup by End User:

• Hospitals
• Clinics
• Vaccination Centres
• Academic and Research Institutes
• Others

Breakup by Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Institutional Sales
• Others

Breakup by Country:

• Saudi Arabia
• UAE
• Qatar
• Bahrain
• Kuwait
• Oman

Saudi Arabia exhibits a clear dominance, accounting for the largest GCC vaccine market share.

Competitive Landscape with Key Players:

The report also examines the competitive landscape within the market and offers comprehensive profiles of major key players.

Key Highlights of the Report:

• Market Performance
• Market Outlook
• Porter's Five Forces Analysis
• Market Drivers and Success Factors
• SWOT Analysis
• Value Chain
• Comprehensive Mapping of the Competitive Landscape

Note: If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.

Browse More Reports:

• https://www.imarcgroup.com/india-semiconductor-market
• https://www.imarcgroup.com/india-tooling-market
• https://www.imarcgroup.com/india-home-decor-market
• https://www.imarcgroup.com/flavoured-milk-market-india
• https://www.imarcgroup.com/silk-industry-in-india

Contact us:

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise.

Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.

This release was published on openPR.